Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Nautilus Biotechnology Inc shares valued at $74,263 were purchased by MARY GODWIN on Dec 17 ’24. At $1.94 per share, MARY GODWIN acquired 38,337 shares.
Also, MARY GODWIN purchased 35,000 shares, netting a total of over 74,588 in proceeds.
Before that, MARY GODWIN had added 60,000 shares to its account. In a trade valued at $131,778, the Officer bought Nautilus Biotechnology Inc shares for $2.20 each.
As published in a research note from Goldman on December 05, 2024, Nautilus Biotechnology Inc [NAUT] has been rated down from a Neutral to a Sell and the price target has been revised to $1.75. Analysts at Guggenheim started covering the stock with ‘”a Buy”‘ outlook in a report released in late June. Earlier on January 06, 2022, Morgan Stanley initiated its rating. Their recommendation was “an Equal-weight” for NAUT stock.
Analyzing NAUT Stock Performance
During the last five days, there has been a drop of approximately -26.88%. Over the course of the year, Nautilus Biotechnology Inc shares have dropped approximately -30.36%. Shares of the company reached a 52-week high of $2.1100 on 01/21/25 and a 52-week low of $1.1000 on 02/27/25. A 50-day SMA is recorded $1.7450, while a 200-day SMA reached $2.3672.
Support And Resistance Levels for Nautilus Biotechnology Inc (NAUT)
According to the 24-hour chart, there is a support level at 1.0767, which, if violated, would cause prices to drop to 0.9833. In the upper region, resistance lies at 1.2867. The next price resistance is at 1.4033. RSI (Relative Strength Index) is 20.84 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.2176, which suggests the price will decrease in the coming days. Percent R is at 89.39%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
